Rationale for Locally Aggressive Treatment of Pancreatic Cancer
Amol K. Narang, MD, discusses the improvement in systemic therapy for treatment of pancreatic cancer in recent years. He says that the combination of various chemotherapies are showing potential in a number of trials.
Amol K. Narang, MD, assistant professor of radiation oncology and molecular radiation sciences, John Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the improvement in systemic therapy for the treatment of pancreatic cancer in recent years. He says that the combination of various chemotherapies are showing potential in a number of trials.
In 2 landmark studies, the combination of FOLFIRINOX [folinic acid, fluorouracil (5-FU), irinotecan, and oxaliplatin] with gemcitabine and paclitaxel has shown significant improvement over the standard of care, gemcitabine alone.
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
